Bioage Labs, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 18 to 25, 2027 · next Jan 18
- 1 fee due Apr 17, 2027The maintenance fee for N-oxide inhibitors of NLRP3 inflammasome (US 11,787,805) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Survival Prediction Using Metabolomic Profiles (US 11,881,311) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,445,981 | Survival Prediction Using Methylomic Profiles In force · High confidence | In force | High confidence | |
| US 10,913,784 | RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,535,661 | RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,881,311 | Survival Prediction Using Metabolomic Profiles In force · High confidence | In force | High confidence | |
| US 11,702,391 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence | |
| US 11,708,334 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence | |
| US 12,215,087 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence | |
| US 12,421,196 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence | |
| US 12,435,043 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence | |
| US 12,673,920 | Inhibitors of NLRP3 Inflammasome In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 6 no status recorded